Drugs / CYNK-101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05207722 | Apr 2022 → Feb 2024 | gastroesophageal junction adenocarcinoma | Celularity Incorporated | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYNK-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05207722 ↗ |
| Modality | Cell therapy | “NK cell product” NCT05207722 ↗ |